Archive Search
255788 items
Shire rejects third Takeda bid, as Allergan drops out
Shire plc (LSE:SHP; NASDAQ:SHPG) said Thursday its board has unanimously rejected three separate takeout offers from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), culminating at the most recent bid valued at £44 billion ($62.7 billion) in which...
Structured outlook
A Cell study capturing hundreds of E. coli mRNA structures makes the case that complex, functionally relevant RNA structures are the rule, not the exception, and builds confidence that mRNAs -- once widely considered undruggable...
Automation navigation
Last year’s approvals of the first two CAR T therapies have prompted the field to get serious about industrializing manufacturing of the cells to improve reproducibility and lower costs. While stakeholders agree that automation will...
FDA says Olumiant's thrombosis signal not a JAK class effect
FDA reviewers raised concerns over a possible increased risk of thrombosis with rheumatoid arthritis candidate Olumiant baricitinib from Eli Lilly and Co. (NYSE:LLY) and partner Incyte Corp. (NASDAQ:INCY).
In briefing documents released Thursday ahead of...
Non-profit KEI sues NIH to block Gilead's anti-CD30 CAR T patent
Non-profit Knowledge Ecology International filed a lawsuit against the National Institutes of Health seeking to invalidate a license granting the Kite Pharma Inc. subsidiary of Gilead Sciences Inc. (NASDAQ:GILD) rights to patents covering an anti-CD30...
CHMP rebuffs AB Science’s masitinib in ALS
EMA’s CHMP recommended against approval of masitinib (AB1010) from AB Science S.A. (Euronext:AB) to treat amyotrophic lateral sclerosis. The company said it plans to address the issues raised by the committee and expects a second...
Synthetic tattoo could detect asymptomatic cancer
A team from ETH Zurich developed a synthetic cellular sensor that darkens a patient's skin in the presence of hypercalcemia -- a disorder associated with many cancers that often arises before signs of cancer --...
Novartis reports first Kymriah sales, Cosentyx miss
Novartis AG (NYSE:NVS; SIX:NOVN) reported $580 million in 1Q18 sales of autoimmune drug Cosentyx secukinumab, shy of analysts' $635 million consensus estimate. The pharma also reported for the first time sales of CAR T therapy...
Panel: Risk/benefit favorable for GW's Epidiolex
An FDA advisory committee voted 13-0 on Thursday that the benefit-risk profile of Epidiolex cannabidiol from GW Pharmaceuticals plc (NASDAQ:GWPH) was favorable to treat seizures in patients with Lennox-Gastaut syndrome and Dravet syndrome ages 2...
Apellis raises $140.3M in follow-on
Apellis Pharmaceuticals Inc. (NASDAQ:APLS) raised $140.3 million late Wednesday through the sale of 5.5 million shares at $25.50 in a follow-on underwritten by Citigroup, J.P. Morgan and Cowen. The price is a 15% discount to...
